{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:39Z","timestamp":1791497919233,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>A novel severe acute respiratory distress syndrome coronavirus type 2 (SARS-CoV-2) has been confirmed as the cause of the global pandemic coronavirus disease 2019 (COVID-19). Different repurposed drugs have been trialed and used in the management of COVID-19. One of these agents was the anti-cancer Selinexor (SXR). SXR is an anti-cancer drug that acts by inhibition of nuclear exportin-1 (XPO1), which inhibits transport of nuclear proteins from the nucleus to the cytoplasm, leading to the induction of cell-cycle arrest and apoptosis. XPO1 inhibitors had antiviral effects, mainly against respiratory syncytial virus (RSV) and influenza virus. SXR inhibits transport of SARS-CoV-2 nuclear proteins to the cytoplasm with further inhibition of SARS-CoV-2 proliferation. SXR has the ability to prevent the development of a cytokine storm in COVID-19 by inhibiting the release of pro-inflammatory cytokines with the augmentation release of anti-inflammatory cytokines. In conclusion, SARS-CoV-2 infection is linked with activation of XPO1, leading to the triggering of inflammatory reactions and oxidative stress. Inhibition of XPO1 by Selinexor (SXR), a selective inhibitor of nuclear export (SINE), can reduce the proliferation of SARS-CoV-2 and associated inflammatory disorders. Preclinical and clinical studies are warranted in this regard.<\/jats:p>","DOI":"10.3389\/fphar.2022.884228","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T06:00:13Z","timestamp":1650952813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Selinexor and COVID-19: The Neglected Warden"],"prefix":"10.3389","volume":"13","author":[{"given":"Gomaa","family":"Mostafa-Hedeab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermeen N.","family":"Welson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber","family":"El-Saber Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Adam","family":"Conte-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"B1","volume-title":"Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID -19","author":"Agree","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fcvm.2021.642181","article-title":"Case Report: Hyperbilirubinemia in Gilbert Syndrome Attenuates COVID -19-induced Metabolic Disturbances","volume":"20","author":"Al-Kuraishy","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s43162-021-00064-x","article-title":"Acute Kidney Injury and COVID-19","volume":"33","author":"Al-Kuraishy","year":"","journal-title":"Egypt. J. Intern. Med."},{"key":"B4","first-page":"1","article-title":"The Prospective Effect of Allopurinol on the Oxidative Stress Index and Endothelial Dysfunction in Covid-19. Inflammation","volume":"24","author":"Al-Kuraishy","year":"","journal-title":"Feb"},{"key":"B5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fmed.2021.644295","article-title":"COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients with Type Ii Diabetes Mellitus: the Anti-inflammatory Role of Metformin","volume":"198","author":"Al-Kuraishy","year":"","journal-title":"Front. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1007\/s11010-021-04232-z","article-title":"The Potential Role of Neopterin in Covid-19: a New Perspective","volume":"476","author":"Al-Kuraishy","year":"2021","journal-title":"Mol. Cel Biochem"},{"key":"B7","first-page":"42","article-title":"Covid-19 and Acute Kidney Injury: A New Perspective","volume":"30","author":"Al-Kuraishy","year":"","journal-title":"IPMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"649128","DOI":"10.3389\/fnut.2021.649128","article-title":"The Looming Effects of Estrogen in Covid-19: a Rocky Rollout","volume":"8","author":"Al-Kuraishy","year":"","journal-title":"Front. Nutr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"666987","DOI":"10.3389\/fcimb.2021.666987","article-title":"Testosterone in COVID-19: An Adversary Bane or Comrade Boon","volume":"11","author":"Al-Kuraishy","year":"","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"749291","DOI":"10.3389\/fimmu.2021.749291","article-title":"Effects of \u03b2-Blockers on the Sympathetic and Cytokines Storms in Covid-19","volume":"12","author":"Al-Kuraishy","year":"2021","journal-title":"Front. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"17590914211057635","DOI":"10.1177\/17590914211057635","article-title":"Covid-19-induced Dysautonomia: a Menace of Sympathetic Storm","volume":"13","author":"Al-Kuraishy","year":"2021","journal-title":"ASN neuroNov"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/bbrj.bbrj_103_20","article-title":"Is Ivermectin\u2013Azithromycin Combination the Next Step for COVID -19?","volume":"4","author":"Al-Kuraishy","year":"2020","journal-title":"Biomed. Biotechnol. Res. J. (Bbrj)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/bbrj.bbrj_103_20","article-title":"Renin\u2013Angiotensin System and Fibrinolytic Pathway in COVID -19: One-Way Skepticism","volume":"4","author":"Al-Kuraishy","year":"2020","journal-title":"Biomed. Biotechnol. Res. J. (Bbrj)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"174196","DOI":"10.1016\/j.ejphar.2021.174196","article-title":"Role of Leukotriene Pathway and Montelukast in Pulmonary and Extrapulmonary Manifestations of Covid-19: The Enigmatic Entity","volume":"904","author":"Al-Kuraishy","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40262-021-01016-y","article-title":"Pharmacokinetics of Selinexor: the First-In-Class Selective Inhibitor of Nuclear export","volume":"60","author":"Bader","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ebiom.2015.07.041","article-title":"Human Exportin-1 Is a Target for Combined Therapy of HIV and AIDS Related Lymphoma","volume":"2","author":"Boons","year":"2015","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"22381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13337-021-00751-x","article-title":"Computational Screening of Potential Drugs against COVID-19 Disease: the Neuropilin-1 Receptor as Molecular Target","volume":"21","author":"Charoute","year":"2022","journal-title":"VirusDisease"},{"key":"B19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3389\/fimmu.2021.646095","article-title":"The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy\u2014A Prospective Longitudinal Study","volume":"12","author":"Copaescu","year":"2021","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0140-6736(03)13976-1","article-title":"B-type Natriuretic Peptide in Cardiovascular Disease","volume":"26362","author":"de Lemos","year":"2003","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"173977","DOI":"10.1016\/j.ejphar.2021.173977","article-title":"Brief Review on Repurposed Drugs and Vaccines for Possible Treatment of COVID-19","volume":"898","author":"De","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fimmu.2021.587146","article-title":"The Relevance of a Physical Active Lifestyle and Physical Fitness on Immune Defense: Mitigating Disease burden, with Focus on COVID -19 Consequences","volume":"5","author":"Filgueira","year":"2021","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8671713","DOI":"10.1155\/2021\/8671713","article-title":"Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19-Mechanisms and Therapeutic Targets","volume":"2021","author":"Fodor","year":"2021","journal-title":"Oxid Med. Cel Longev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.002386","article-title":"A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing","author":"Gordon","year":"2020","journal-title":"bioRxiv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week Selinexor, Bortezomib, and Dexamethasone versus Twice-Per-Week Bortezomib and Dexamethasone in Patients with Multiple Myeloma (BOSTON): a Randomised, Open-Label, Phase 3 Trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00705-021-04958-7","article-title":"The Roles of Signaling Pathways in SARS-CoV-2 Infection; Lessons Learned from SARS-CoV and MERS-CoV","volume":"166","author":"Hemmat","year":"2021","journal-title":"Arch. Virol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2024302118","DOI":"10.1073\/pnas.2024302118","article-title":"Drugs Repurposed for COVID-19 by Virtual Screening of 6,218 Drugs and Cell-Based Assay","volume":"118","author":"Jang","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e01684","DOI":"10.1128\/JVI.01684-18","article-title":"Verdinexor (KPT-335), a Selective Inhibitor of Nuclear export, Reduces Respiratory Syncytial Virus Replication In Vitro","volume":"1593","author":"Jorquera","year":"2019","journal-title":"J. Virol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (SADAL): a Single-Arm, Multinational, Multicentre, Open-Label, Phase 2 Trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Acts through NF-\u039ab Deactivation and Combines with Proteasome Inhibitors to Synergistically Induce Tumor Cell Death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","first-page":"192105115","DOI":"10.1016\/j.antiviral.2021.105115","article-title":"Selinexor, a Novel Selective Inhibitor of Nuclear export, Reduces SARS-CoV-2 Infection and Protects the Respiratory System In Vivo","volume":"192","author":"Kashyap","year":"2021","journal-title":"Antivir. Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.virusres.2006.06.005","article-title":"Over-expression of Severe Acute Respiratory Syndrome Coronavirus 3b Protein Induces Both Apoptosis and Necrosis in Vero E6 Cells","volume":"122","author":"Khan","year":"2006","journal-title":"Virus. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-021-00568-7","article-title":"Characterization of SARS-CoV-2 Proteins Reveals Orf6 Pathogenicity, Subcellular Localization, Host Interactions and Attenuation by Selinexor","volume":"11","author":"Lee","year":"2021","journal-title":"Cel Biosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102293","DOI":"10.1016\/j.isci.2021.102293","article-title":"ORF8 Contributes to Cytokine Storm during SARS-CoV-2 Infection by Activating IL-17 Pathway","volume":"2324","author":"Lin","year":"2021","journal-title":"Iscience"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3389\/fmicb.2017.01171","article-title":"CRM1 Inhibitors for Antiviral Therapy","volume":"8","author":"Mathew","year":"2017","journal-title":"Front. Microbiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3389\/fpubh.2020.582932","article-title":"Coronavirus Disease (COVID -19): Comprehensive Review of Clinical Presentation","volume":"15","author":"Mehta","year":"2021","journal-title":"Front. Public Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"28344","DOI":"10.1073\/pnas.2016650117","article-title":"SARS-CoV-2 Orf6 Hijacks Nup98 to Block STAT Nuclear Import and Antagonize Interferon Signaling","volume":"117","author":"Miorin","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","article-title":"COVID-19: Current Understanding of its Pathophysiology, Clinical Presentation and Treatment","volume":"197","author":"Parasher","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective Inhibitors of Nuclear export (SINE)--a Novel Class of Anti-cancer Agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167221","article-title":"Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection","volume":"11","author":"Perwitasari","year":"2016","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/stresses1020010","article-title":"How May Obesity-Induced Oxidative Stress Affect the Outcome of COVID-19 Vaccines? Lesson Learned from the Infection","volume":"1","author":"Pivonello","year":"2021","journal-title":"Stresses"},{"key":"B42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","article-title":"Selinexor for the Treatment of Multiple Myeloma","volume":"321","author":"Podar","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"B43","article-title":"Clinical Presentation and Outcomes of the First Patients with COVID-19 in Argentina: Results of 207079 Cases from a National Database","volume":"1116","author":"Sch\u00f6nfeld","year":"2021","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2478\/pjvs-2013-0106","article-title":"Influence of Importin Alpha\/beta and Exportin 1 on Equine Herpesvirus Type 1 (EHV-1) Replication in Primary Murine Neurons","volume":"16","author":"Slo\u0144ska","year":"2013","journal-title":"Pol. J. Vet. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"12248","DOI":"10.1038\/s41598-018-30686-1","article-title":"Anti-tumor Efficacy of Selinexor (KPT-330) in Gastric Cancer Is Dependent on Nuclear Accumulation of P53 Tumor Suppressor","volume":"8","author":"Subhash","year":"2018","journal-title":"Sci. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First Global Approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/cns.12501","article-title":"A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus","volume":"22","author":"Tajiri","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"IJH04","DOI":"10.2217\/ijh-2018-0001","article-title":"Nuclear Transport Inhibition in Acute Myeloid Leukemia: Recent Advances and Future Perspectives","volume":"7","author":"Talati","year":"2018","journal-title":"Int. J. Hematol. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.drudis.2020.06.014","article-title":"Exportin 1 Inhibition as Antiviral Therapy","volume":"125","author":"Uddin","year":"2020","journal-title":"Drug Discov. Today"},{"key":"B50","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1365-2443.2012.01607.x","article-title":"Ligand-dependent Nucleo-Cytoplasmic Shuttling of Peroxisome Proliferator-Activated Receptors, PPAR\u03b1 and PPAR\u03b3","volume":"17","author":"Umemoto","year":"2012","journal-title":"Genes Cells"},{"key":"B51","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ygyno.2019.11.012","article-title":"Phase 2 Study of the Exportin 1 Inhibitor Selinexor in Patients with Recurrent Gynecological Malignancies","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0168-1702(01)00263-5","article-title":"Inhibition of Nuclear export of Ribonucleoprotein Complexes of Influenza Virus by Leptomycin B","volume":"77","author":"Watanabe","year":"2001","journal-title":"Virus. Res."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200043","article-title":"In Vitro toxicity and Efficacy of Verdinexor, an Exportin 1 Inhibitor, on Opportunistic Viruses Affecting Immunocompromised Individuals","volume":"13","author":"Widman","year":"2018","journal-title":"PloS one"},{"key":"B54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/nyas.14512","article-title":"SARS-CoV-2 Infection, COVID-19 Pathogenesis, and Exposure to Air Pollution: What Is the Connection?","volume":"1486","author":"Woodby","year":"2021","journal-title":"Ann. N. Y Acad. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.bbrc.2018.07.112","article-title":"KPT-330, a Potent and Selective CRM1 Inhibitor, Exhibits Anti-inflammation Effects and protection against Sepsis","volume":"503","author":"Wu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bbrc.2021.03.068","article-title":"A Tissue- and Gender-specific Regulation of the SARS-CoV-2 Receptor ACE2 by P53 in Pigs","volume":"553","author":"Zhang","year":"2021","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2147\/dddt.s303928","article-title":"Establishment and Verification of UPLC-MS\/MS Technique for Pharmacokinetic Drug-Drug Interactions of Selinexor with Posaconazole in Rats","volume":"15","author":"Zhou","year":"2021","journal-title":"Dddt"},{"key":"B58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV\/SARS-CoV-2","volume":"166","author":"Zhou","year":"2020","journal-title":"Cell Discov"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.884228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T06:00:22Z","timestamp":1650952822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.884228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":58,"alternative-id":["10.3389\/fphar.2022.884228"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.884228","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"article-number":"884228"}}